Extended Data Fig. 9: Functional drug sensitivity landscape of the Beat AML cohort.
From: Functional genomic landscape of acute myeloid leukaemia
a, Co-occurrences with regard to WGCNA gene expression clusters and/or mutational events (coefficients) were detected by multivariate modelling with respect to ibrutinib response (resistance (blue); sensitivity (red)) and the degree of correlation is shown in the stacked bar plot (top). All coefficients that appear in 25% of the bootstrapped sample sets are shown as segments of the circle. Segment width (the coloured ring) corresponds to the percentage of bootstrapped samples in which that coefficient appears (quantified above the dotted line). The variables appear in descending order clockwise starting at 12 o’clock. Each link indicates pairwise co-occurrence of mutational events and gene expression clusters (width represents frequency of the co-occurrence). The largest co-occurrence for each coefficient is quantified. b, The capacity of differential gene expression to distinguish the 20% most ibrutinib-sensitive (n = 46) from 20% most resistant (n = 44) specimens is shown on a principal component plot (n = 239 patient samples were tested for ibrutinib sensitivity and RNA sequencing). For the number of samples used to correlate each drug with gene expression and perform LASSO regression, see Supplementary Table 17.
